Vietnam\u2019s pharmaceutical market is among the fastest growing in Asia. With a population of over 100 million, rising healthcare expenditure, an expanding middle class, and an increasingly sophisticated regulatory framework, Vietnam offers substantial opportunities for foreign pharmaceutical manufacturers and distributors.<\/p>\n
However, market entry and distribution are tightly regulated. The applicable framework is shaped not only by domestic legislation\u2014primarily the Law on Pharmacy and its guiding decrees and circulars\u2014but also by Vietnam\u2019s commitments under the WTO, the EU\u2013Vietnam Free Trade Agreement (EVFTA) and the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP).<\/p>\n
Understanding how these layers interact is essential for structuring a compliant and commercially viable market entry strategy.<\/p>\n
I. The Regulatory Architecture: A Structured Overview<\/p>\n
Foreign pharmaceutical companies must navigate three key regulatory pillars:<\/p>\n
1.\tMarket access rights (What activities are legally permitted?)
\n2.\tPharmaceutical product registration (Can the product be lawfully marketed?)
\n3.\tImportation and distribution structure (How is the product brought into and circulated within Vietnam?)<\/p>\n
Each of these is influenced by Vietnam\u2019s international treaty commitments.<\/p>\n
II. WTO Commitments \u2013 Baseline Market Access<\/p>\n
Vietnam acceded to the WTO in 2007. Its WTO Schedule of Commitments established the baseline for foreign participation in the pharmaceutical sector.<\/p>\n
1. Distribution Services Commitments<\/p>\n
Under its WTO commitments, Vietnam opened distribution services to foreign investors, but with important limitations:<\/p>\n
\u2022\tForeign-invested enterprises (FIEs) may engage in importation and distribution of most goods.
\n\u2022\tPharmaceutical products remain a sensitive sector.
\n\u2022\tForeign-invested companies are generally not permitted to distribute pharmaceutical products directly to retail outlets or consumers.
\n\u2022\tDistribution at the retail level is reserved for Vietnamese-owned enterprises or entities meeting strict pharmacy licensing requirements.<\/p>\n
In practice, this means:
\n\u2022\tA foreign pharmaceutical company may establish a wholly foreign-owned enterprise (WFOE) to import pharmaceuticals.
\n\u2022\tHowever, physical distribution to hospitals, clinics, and pharmacies must be conducted by licensed Vietnamese pharmaceutical distributors or through compliant structures under the Law on Pharmacy.<\/p>\n
2. Commercial Presence<\/p>\n
WTO commitments allow:<\/p>\n
\u2022\t100% foreign-owned enterprises for importation of pharmaceuticals.
\n\u2022\tEstablishment of representative offices for market research and liaison purposes (but no revenue-generating activity).<\/p>\n
The WTO framework therefore opened the door but left the core distribution function heavily regulated.<\/p>\n
III. EVFTA Commitments \u2013 Deepened Market Access for EU Companies<\/p>\n
The EU\u2013Vietnam Free Trade Agreement, effective since August 2020, significantly enhanced market access conditions for EU pharmaceutical companies.<\/p>\n
1. Tariff Elimination<\/p>\n
\u2022\tAlmost all pharmaceutical products originating from the EU are subject to immediate or phased tariff elimination.
\n\u2022\tThis has improved price competitiveness for EU-manufactured medicines.<\/p>\n
2. Regulatory Transparency and Cooperation<\/p>\n
The EVFTA contains strong commitments regarding:<\/p>\n
\u2022\tTransparency in regulatory procedures
\n\u2022\tPublication of pharmaceutical pricing and reimbursement rules
\n\u2022\tFair and objective criteria for marketing authorization
\n\u2022\tProtection of confidential business information<\/p>\n
These provisions are particularly relevant during product registration and public procurement.<\/p>\n
3. Government Procurement Access<\/p>\n
Under the EVFTA:<\/p>\n
\u2022\tEU companies gain improved access to public procurement markets, including certain central-level healthcare institutions.
\n\u2022\tThis is critical, as public hospital tenders account for a substantial portion of pharmaceutical sales in Vietnam.<\/p>\n
4. Intellectual Property and Data Protection<\/p>\n
The EVFTA strengthens:<\/p>\n
\u2022\tData exclusivity for pharmaceutical products.
\n\u2022\tPatent term adjustments in certain circumstances.
\n\u2022\tEnforcement mechanisms against infringement.<\/p>\n
For innovative pharmaceutical companies, these protections are commercially significant.<\/p>\n
IV. CPTPP Commitments \u2013 Regional Integration and Standards<\/p>\n
Vietnam\u2019s participation in the CPTPP further reinforces its integration into high-standard trade frameworks.<\/p>\n
1. Market Access<\/p>\n
The CPTPP consolidates and, in some areas, improves upon WTO commitments:<\/p>\n
\u2022\tGreater transparency in pharmaceutical approval processes.
\n\u2022\tCommitments regarding non-discriminatory treatment of foreign suppliers.<\/p>\n
2. Regulatory Coherence<\/p>\n
CPTPP encourages:<\/p>\n
\u2022\tGood Regulatory Practices (GRP).
\n\u2022\tScience-based decision-making.
\n\u2022\tClear administrative timelines.<\/p>\n
While CPTPP does not radically alter distribution restrictions, it strengthens procedural fairness and predictability.<\/p>\n
V. Domestic Legal Framework \u2013 The Law on Pharmacy<\/p>\n
Beyond treaty commitments, the Law on Pharmacy (2016, as amended) and implementing regulations govern:<\/p>\n
\u2022\tMarketing authorization
\n\u2022\tImport licensing
\n\u2022\tDistribution
\n\u2022\tStorage (GDP compliance)
\n\u2022\tManufacturing (GMP compliance)<\/p>\n
Foreign companies must strictly align their structure with domestic law, regardless of treaty entitlements.<\/p>\n
VI. Step-by-Step Market Entry \u2013 Best Practice Approach<\/p>\n
A compliant and efficient market entry typically follows a structured pathway:<\/p>\n
Step 1: Strategic Structuring Decision<\/p>\n
Foreign pharmaceutical companies must determine:<\/p>\n
\u2022\tRepresentative office?
\n\u2022\tWholly foreign-owned import company?
\n\u2022\tJoint venture with Vietnamese distributor?
\n\u2022\tContract-based distribution model?<\/p>\n
Best practice:<\/p>\n
Most foreign manufacturers choose either:<\/p>\n
\u2022\tA wholly foreign-owned import company combined with licensed local distributors; or
\n\u2022\tA strong Vietnamese distribution partner with nationwide coverage.<\/p>\n
The choice depends on long-term control objectives and operational scale.<\/p>\n
Step 2: Establish Legal Presence<\/p>\n
Options include:<\/p>\n
Representative Office<\/p>\n
\u2022\tMarket research and regulatory liaison only.
\n\u2022\tNo direct commercial activity.<\/p>\n
Wholly Foreign-Owned Enterprise<\/p>\n
\u2022\tLicensed for importation of pharmaceuticals.
\n\u2022\tMust obtain:
\no\tInvestment Registration Certificate (IRC)
\no\tEnterprise Registration Certificate (ERC)
\no\tBusiness license for pharmaceutical trading
\no\tEligibility certificate for pharmaceutical business<\/p>\n
Step 3: Marketing Authorization (Drug Registration)<\/p>\n
No pharmaceutical product may be marketed without a valid Marketing Authorization (MA).<\/p>\n
Key requirements include:<\/p>\n
\u2022\tDossier submission to the Drug Administration of Vietnam (DAV).
\n\u2022\tTechnical documentation (quality, safety, efficacy).
\n\u2022\tCertificate of Pharmaceutical Product (CPP).
\n\u2022\tGMP compliance of manufacturing site.
\n\u2022\tProduct samples (where required).<\/p>\n
Timelines can be lengthy. Early preparation is critical.<\/p>\n
Best practice:
\nEngage experienced regulatory advisors and ensure dossier consistency across jurisdictions to avoid delay.<\/p>\n
Step 4: Import Licensing<\/p>\n
Each shipment requires:<\/p>\n
\u2022\tImport authorization referencing the valid MA.
\n\u2022\tCustoms clearance documentation.
\n\u2022\tCompliance with labeling requirements in Vietnamese.<\/p>\n
Temperature-controlled logistics must comply with Good Distribution Practice (GDP).<\/p>\n
Step 5: Distribution Model Implementation<\/p>\n
Foreign companies cannot freely retail pharmaceutical products.<\/p>\n
Typical structure:<\/p>\n
1.\tImport via licensed entity.
\n2.\tTransfer to:<\/p>\n
o\tLicensed Vietnamese distributors; or
\no\tHospitals through tender process; or
\no\tWholesalers compliant with GDP.<\/p>\n
Retail pharmacy operations require separate pharmacy licenses and pharmacist supervision.<\/p>\n
Step 6: Participation in Public Tenders<\/p>\n
Hospital tenders are a key sales channel.<\/p>\n
Important considerations:<\/p>\n
\u2022\tProduct classification (innovative vs. generic).
\n\u2022\tPricing registration.
\n\u2022\tCompliance with tender documentation.
\n\u2022\tCompetitive bidding strategy.<\/p>\n
EVFTA and CPTPP transparency provisions enhance procedural fairness, but local compliance remains decisive.<\/p>\n
Step 7: Ongoing Compliance<\/p>\n
Continuous obligations include:<\/p>\n
\u2022\tPharmacovigilance reporting.
\n\u2022\tAdvertising approval for pharmaceuticals.
\n\u2022\tPeriodic license renewals.
\n\u2022\tPricing declaration requirements.
\n\u2022\tInspection readiness.<\/p>\n
Regulatory scrutiny in the pharmaceutical sector is intensive.<\/p>\n
VII. Recommended Market Entry Structure<\/p>\n
A feasible and workable structure for most foreign pharmaceutical companies is:<\/p>\n
1.\tEstablish a wholly foreign-owned import company.
\n2.\tSecure product registrations under the company\u2019s name.
\n3.\tConclude distribution agreements with 2\u20133 strong local distributors (regional diversification).
\n4.\tBuild internal regulatory and compliance oversight capacity.
\n5.\tMaintain direct engagement with key hospitals and medical opinion leaders through compliant channels.<\/p>\n
This structure ensures:<\/p>\n
\u2022\tControl over product registration.
\n\u2022\tProtection of intellectual property.
\n\u2022\tDiversified distribution risk.
\n\u2022\tLong-term scalability.<\/p>\n
For EU-based companies, leveraging EVFTA procurement access and tariff advantages provides additional competitive positioning.<\/p>\n
VIII. Key Risks and Practical Pitfalls
\n\u2022\tUnderestimating registration timelines.
\n\u2022\tStructuring distribution contrary to Law on Pharmacy restrictions.
\n\u2022\tInadequate GDP\/GMP documentation.
\n\u2022\tWeak tender strategy.
\n\u2022\tInsufficient local compliance oversight.<\/p>\n
Regulatory errors in pharmaceuticals carry significant financial and reputational risk.<\/p>\n
IX. Conclusion<\/p>\n
Vietnam offers substantial growth potential for foreign pharmaceutical companies. WTO commitments created the foundation; the EVFTA and CPTPP have deepened transparency, improved intellectual property protection, and enhanced procurement access.<\/p>\n
Yet market access remains structured and compliance driven. Successful entry requires careful legal structuring, meticulous regulatory preparation, and disciplined distribution management.<\/p>\n
Those who approach Vietnam with strategic planning, regulatory rigor, and a long-term commitment to compliance will find a dynamic and rewarding market\u2014one that continues to evolve in sophistication and opportunity.<\/p>\n
***<\/p>\n
Please do not hesitate to contact Dr. Oliver Massmann under omassmann@duanemorris.com if you have any questions or want to know more details on the above. Dr. Oliver Massmann is the General Director of Duane Morris Vietnam LLC.<\/p>\n","protected":false},"excerpt":{"rendered":"
Vietnam\u2019s pharmaceutical market is among the fastest growing in Asia. With a population of over 100 million, rising healthcare expenditure, an expanding middle class, and an increasingly sophisticated regulatory framework, Vietnam offers substantial opportunities for foreign pharmaceutical manufacturers and distributors. However, market entry and distribution are tightly regulated. The applicable framework is shaped not only … <\/p>\n
Continue reading “VIETNAM – FOREIGN PHARMACEUTICAL COMPANIES – IMPORT AND DISTRIBUTION- WHAT YOU MUST KNOW”<\/span><\/a><\/p>\n","protected":false},"author":24,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"ppma_author":[1007],"class_list":["post-1881","post","type-post","status-publish","format-standard","hentry","category-vietnam-general"],"authors":[{"term_id":1007,"user_id":24,"is_guest":0,"slug":"omassmann","display_name":"Dr. Oliver Massmann","avatar_url":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-content\/uploads\/sites\/19\/2014\/08\/massmannoliver-125x150.jpg","author_category":"1","last_name":"Massmann","first_name":"Dr. Oliver","job_title":"","user_url":"http:\/\/www.duanemorris.com\/attorneys\/olivermassmann.html","description":"Read Oliver's bio.<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/posts\/1881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/comments?post=1881"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/posts\/1881\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/media?parent=1881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/categories?post=1881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/tags?post=1881"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/vietnam\/wp-json\/wp\/v2\/ppma_author?post=1881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}